Analgesic effects and metabolome analyses of laser- and electro-acupuncture combined therapies in paclitaxel-induced neuropathic pain model
School of Korean Medicine, Dongshin University, Naju, Jeonnam, Republic of Korea
Department of Companion Animal Industry, College of Health and Welfare, Dongshin University, Naju, Jeonnam, Republic of Korea
Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea
School of Biomedical Sciences, Charles Sturt University, Bathurst, NSW, Australia
Abstract
Introduction
Allodynia, which can be induced by paclitaxel administration, is the presence of pain as a result of a stimulus that does not usually provoke pain. Many studies have investigated the analgesic efficacy of acupuncture, including laser acupuncture (LA) and electroacupuncture (EA). Although pain-related diseases are relatively common, few studies have analyzed the analgesic effects and mechanisms of LA combined with EA. The purpose of this study was to investigate the therapeutic effect and mechanism of manual acupuncture (MA), EA, LA, and combined therapy (LA + EA) in a paclitaxel-induced allodynia rat model.
Methods
A total of 56 rats were classified into eight groups: a normal (Nor, n = 7), a control (Con, n = 7), an MA (n = 7), an EA (n = 7), a 650-nm LA (650LA, n = 7), an 830-nm LA (830LA, n = 7), a 650-nm LA combined with EA (650LA + EA, n = 7), and an 830-nm LA combined with EA group (830LA + EA, n = 7). Allodynia was induced by intraperitoneal injection of 2 mg/kg of paclitaxel every other day for a total of four times except the Nor group. Acupuncture treatments were conducted at the points of Jungwan (CV12) and Joksamni (ST36) once every other day for 6 min, for a total of nine times. Withdrawal response reaction times and force intensity of the foot were measured before the start of the experiment, after the 4th paclitaxel administration (day 8), and after the 9th and last treatment (day 15). On the 16th day, mRNA and protein expression in the spinal nerves was assessed, and a metabolome analysis of the animals’ feces was performed.
Results and discussion
Our analyses show that 650LA + EA treatment resulted in an upregulation of protein expression related to pain relief and nerve regeneration, whereas 830LA + EA treatment led to significant changes in metabolomes. This study demonstrates that a combination treatment of EA and LA can suppress allodynia and promote upregulation of protein expression related to nerve regeneration and is effective in changing the intestinal microbiome. Further large-scale research is required to assess the exact mechanism underlying the therapeutic effect of this combination treatment in pain-related diseases.
Untitled section
Keywords: laser-and electro-acupuncture combined therapy, paclitaxel, allodynia, endocannabinoids, metabolome analyses
Article notes
Untitled section
Received 2023 Jan 30; Accepted 2023 Mar 29; Collection date 2023.
Introduction
The expression of pathological pain experienced by patients in clinical practice varies greatly between individuals. Complaints can be divided into those of spontaneous pain, hyperalgesia, and allodynia, which is defined as pain caused by stimuli that do not normally cause pain (1). Allodynia, that is, abnormal stimulus-induced nociceptive pain, can be classified into dynamic mechanical, static mechanical, heat, and motor allodynia (2, 3). Otherwise, hyperalgesia is an increased pain due to a stimulus which usually provokes pain (4). Neuropathic pain, which is spontaneous and persistent, often requires adjuvant treatment, such as combined analgesic administration or other interventional pain treatments (2, 5). Propagation of nociceptive pain is transmitted to the somatosensory cortex by secretion of glutamate, γ-aminobutyric acid (GABA), or substance-P from the presynaptic neurons of peripheral nerves and binding to postsynaptic neurons (6). Neuronal pain processing, perception, and modulation have very complex mechanisms, and various proteins including cannabinoid receptor type 1 (CB1R) and fatty acid amide hydrolase (FAAH), c-Fos proto-oncogene (c-Fos), neuronal nuclear antigen (NeuN), and neuronal phosphoproteins, including synapsin I and microtubule-associated protein 2 (MAP2) are involved in the pain pathways (7). CB1R and FAAH belong to endocannabinoid system, which interacts with various endogenous ligands and neurotransmitters with neuroprotective, analgesic, and anti-inflammatory properties (8). c-Fos is present in neurons in response to stimulation, and synapsin 1 regulates synapse formation and neurotransmitter release (9, 10). NeuN and MAP2 regulate neuronal growth and regeneration (11–13). These are closely related to analgesic effects by the inhibition of presynaptic neurotransmitter and neuropeptide release, modulation of postsynaptic neuron, and reductions in neuroinflammatory signaling (14).
In clinical practice, paclitaxel is used alone or in combination for the treatment of breast, lung, ovarian, and gastric cancer; it inhibits the differentiation and cell cycle arrest in the Sub-G1 and G2/M phases, eventually leading to apoptosis (15). Cell surface changes, cell destruction, and formation of apoptotic bodies by phagocytes occur, which then proceed as a result of the action of the immune system (16). However, paclitaxel inhibits tumor growth and affects normal cells simultaneously, resulting in damage to mucous membranes, blood vessels, and neurons with a short cell cycle; this causes neuropathic side effects such as pain, tingling, cold sensitivity, and numbness (17). These side effects are thought to be caused by an immune response following the production of pro-inflammatory mediators and the development of central sensitization and pain behavior caused by paclitaxel administration (18).
Many studies have investigated the efficacy of acupuncture in Oriental medicine. Acupuncture contributes to angiogenesis and granulation and promotes tissue regeneration of wounds in mice (19). Other studies have reported adjustment of the primary somatosensory cortex by acupuncture (20), improvement of colitis by electroacupuncture (EA) treatment of sensitive skin points and acupuncture points (21), and an insomnia treatment effect of acupuncture (22). In addition, the combination of EA and laser acupuncture (LA) with modern science and technology as well as with traditional acupuncture is used as an acupoint treatment method. Previous studies have reported combined effects of LA and EA in a collagenase-induced osteoarthritis rat model (23) and in human patients with knee osteoarthritis (24).
Among the various acupoints, Jungwan (CV12) and Joksamni (ST36) can easily be designated in experimental animals through bone proportional measurements (25). ST36 acupuncture is used for pain relief and immunity, such as suppression of IgE and the effect of Th1/Th2 regulation (26), while CV12 is the mother blood of the stomach, which is a specific acupuncture point where the energy of the intestines gathers (27). These two acupoints are assigned to meridians that are closely associated with the spleen and stomach and are related to intestinal microorganisms and the brain–gut microbiota axis, which is involved in the body’s immunity and control of the brain (28).
The objective of this study was to evaluate the analgesic effect and mechanism of manual acupuncture (MA), EA, LA, and the combination therapy of LA and EA by assessing pathological pain through von Frey filaments and analyses of mRNA and protein expression as well as metabolomes in a paclitaxel-induced allodynia rat model.
Materials and methods
Animals and study design
A total of 56 10-week-old Sprague Dawley rats weighing approximately 330–350 g, were included in this study. They were first allowed to adapt to the laboratory environment, with a sufficient supply of feed and water and at a constant temperature of 24 ± 1°C and humidity of 40–60% for 7 days. Water and feed were provided ad libitum during the entire experimental period. The study was approved by the Committee of Animal Care and Experiments of Dongshin University, Republic of Korea (DSU2020-04-01). The rats were randomly divided into eight groups: a normal group (Nor, n = 7), a control group (Con, n = 7), a MA group (n = 7), an EA group (n = 7), a 650-nm LA group (650LA, n = 7), an 830-nm LA group (830LA, n = 7), a 650-nm LA combined with EA group (650LA + EA, n = 7), and an 830-nm LA combined with EA group (830LA + EA, n = 7; Table 1). Except in the Nor group, 2 mg/kg paclitaxel was injected intraperitoneally every 2 days for a total of four times to induce allodynia.
| Group | Acupoint | Contents |
|---|---|---|
| Nor | – | – |
| Con | – | PT (2 mg/kg, IP) |
| MA | CV12, ST36 | PT (2 mg/kg, IP) + MA |
| EA | CV12, ST36 | PT (2 mg/kg, IP) + EA |
| 650LA | CV12, ST36 | PT (2 mg/kg, IP) + 650 nm LA |
| 830LA | CV12, ST36 | PT (2 mg/kg, IP) + 830 nm LA |
| 650LA + EA | CV12, ST36 | PT (2 mg/kg, IP) + 650 nm LA + EA |
| 830LA + EA | CV12, ST36 | PT (2 mg/kg, IP) + 830 nm LA + EA |
All acupuncture treatments were performed at CV12 and ST36 once every other day for 6 min, for a total of nine times. EA was conducted at 50 Hz and 4 mA and LA at 50 Hz and 20 mW. The acupuncture points were CV12 on the upper abdomen (Figure 1A), and ST36 on the anterior aspect of the leg (Figure 1B). The anatomical locations of the acupoints were stimulated as previously described (29, 30). EA needles with a diameter of 0.3 mm were inserted into the skin and underlying muscles with a depth of 3–4 mm. In the case of the ST36 position, the right and left side was stimulated alternately at each treatment cycle. For the LA and EA combination treatment, 3 min of LA treatment were followed by 3 min of EA treatment. Table 2 shows the specific conditions of the stimulator device used for the combined application of laser and electric acupuncture. A laser and electrical stimulator system (ELLEISE; WONTECH Co. Ltd., Republic of Korea) was used for laser acupuncture and electrical stimulation, and an optical fiber was inserted into an empty stainless cannula for invasive laser acupuncture stimulation (Figures 1C–E). During all acupuncture treatments including EA and LA, rats were under general anesthesia by inhalation anesthetics with 2.5% isoflurane and 80% O2.
| No | Classification | Specification | |
|---|---|---|---|
| 1 | Wavelength | 650 nm ± 20 nm, 830 nm ± 20 nm | |
| 2 | Laser diode | InGaAlP (650 nm), GaAlAs (830 nm) | |
| 3 | Laser transmission method | Fiber-optic acupuncture | |
| 4 | Laser irradiation diameter | 0.15 mm ± 20% | |
| 5 | Laser Output | Optical fiber beam transmission device (optical fiber) | 650 nm: 10 mW, 20 mm, 30 mm ± 20% 830 nm: 10 mm, 20 mm, 30 mm ± 20% |
| Modulation frequency | 650 nm: 1 ~ 200 Hz 830 nm: 1 ~ 200 Hz | ||
| 6 | Electrical stimulator | Voltage | Max. 5.0 V/0.1 V increase or decrease in units |
| Output waveform | Sine, Triangular, Pulse | ||
| Modulation frequency | 1 Hz ~ 200 Hz | ||
| 7 | Output time | Min 1 min ~ Max 30 min/1 min unit | |
| 8 | Type and degree of protection against electric shocks | Grade 1, BF type | |
| 9 | Laser classification by IEC 60825–1 | CLASS 3B | |
| 10 | User interface | Touch LCD method (7 inches) | |
| 11 | Equipment size | 400 mm (W) × 259 mm (D) × 200 mm (H) | |
| 12 | Weight | 4.58 kg | |
| 13 | Cooling system | Air-cooled | |
| 14 | Electrical rating | AC 220 V, 60 Hz Power consumption: 200VA | |
Withdrawal response reaction times and force intensity in the foot were measured using a dynamic plantar aesthesiometer three times: before the start of the experiment, after the 4th paclitaxel administration (day 8), and after the 9th and last treatment (day 15). On the 16th day, all animals were euthanized, sections of lumber (L3–L6) and sacral (S1, S2) segments of the spinal cord and feces were collected, RNA was isolated from the spinal nerves, and a metabolome analysis of the feces was performed. The mRNA expression of CB1R and FAAH and the protein expression of c-Fos, CB1R, FAAH, NeuN, synapsin I, and MAP2 were analyzed.
Pain behavioral test
Withdrawal response reaction times and force intensity were measured by stimulating the sole of the foot with von Frey stimuli using a dynamic plantar aesthesiometer (UGO BASILE 37450, Italy) three times: before the start of the experiment, after the 4th paclitaxel administration (day 8), and after the 9th and last treatment (day 15). For the measurement, the animal was moved to a cage made of netting and stabilized for 5 min; then the withdrawal response was assessed. The degree of allodynia caused by the stimulation was measured as the withdrawal response reaction time of the foot (in seconds; time taken for the stimulator to touch the sole of the foot and fall off) and the force intensity (in g, force at the moment the animal avoids the stimulator) on the affected side at an intensity of 0–50 g.
RNA isolation and reverse transcription-polymerization chain reaction (RT-PCR)
For isolation of RNA, 1 ml TRIzol Reagent (Life Technologies, United States) were added to spinal nerve tissue (100 mg) and homogenized in a homogenizer (Precellys 24, Bertin Technologies, France), with 200 μl chloroform (Sigma, United States) added to the homogenate. After shaking for 15 s, the mixture was left at room temperature for 5 min and then centrifuged for 5 min at 4°C and 14,000 rpm in a centrifuge (Centrifuge 5415 R; Eppendorf, Germany) to remove cell residues. Then, the supernatant was separated, 500 μl isopropanol (Sigma, United States) were added, the mixture was left at room temperature for 5 min, and centrifuged again at 4°C and 14,000 rpm for 8 min. Diethylpyrocarbonate was added to the obtained RNA pellet in 70% ethanol and stored in a refrigerator. The pellet was separated by centrifugation at 4°C and 7,500 rpm for 5 min, and the remaining ethanol was left at room temperature for 5 min to evaporate, then dissolved in diethylpyrocarbonate-treated water. RNA purity and concentration were measured using the OD260 value on a spectrophotometer (Biophotometer, Eppendorf, Germany). A cDNA Synthesis Master Mix (LeGene Biosciences, United States) was used for amplification by a cDNA synthesis process at 42°C for 1 h and an RTase inactivation process at 94°C for 5 min, on a Mastercycler gradient machine (Eppendorf, Germany).
SB-Green qPCR Master Mix (LeGene Biosciences, United States) was used for amplification on a CFX Connect Optics Module (BIO RAD, Singapore). PCR included a 2-min pre-denaturation process at 95°C and a 50-s denaturation process at 95°C, and the Tm (°C) of each gene was a 10-s annealing process and a 30-s extension process at 72°C. A repeat process of 39 cycles was performed, and cDNA was amplified through a melting process.
Western blot
The tissue was homogenized using pro-prep protein extraction buffer and beads, then incubated on ice for 30 min and centrifuged at 13,300 rpm for 20 min at 4°C; the supernatant was collected. After quantifying the protein following the BCA method, 20 μg of the corresponding amount was put into 5 × sample buffer, inactivated at 100°C for 5 min, and then electrophoresed on a 10% SDS polyacrylamide gel. The separated proteins were transferred to a PVDF membrane and blocked in 5% skim milk for 60 min. The primary antibody was incubated overnight at 4°C, washed three times for 5 min with Tris-buffered saline Tween-20 (TBST, 10 mM Tris–HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.6) buffer, and the secondary antibody was incubated at 1:5,000 and attached at room temperature for 2 h. For protein detection, the membrane was washed with TBST buffer three times for 10 min, ECL (Thermo, United States) was applied to the membrane for 2 min, and measurements were performed using LAS equipment (Amersham imager 600; GE, United States).
Statistical analysis
Statistical analyses were performed using GraphPad Prism Statistics software version 6.01 (United States). All continuous data are presented as means ± standard error. Normal distribution assumption was confirmed using the Kolmogorov–Smirnov test. Values were compared between groups using one-way ANOVA and Tukey’s multiple comparisons test. A p value of < 0.05 was considered statistically significant. The PLS-DA score was analyzed by the permutation test analysis using SIMCA software (SIMCA 15.0; Umetics, Sweden).
Results
Withdrawal response reaction times and force intensity
Table 3 shows the effect of each treatment on the von Frey reaction times for paclitaxel-induced allodynia. Compared to the Nor group, the Con group showed significantly shorter von Frey reaction times on days 8 and 15 (p < 0.01). Compared to the Con group, the MA, EA, and 650LA + EA groups showed significantly longer von Frey reaction times on day 8 (p < 0.01), and the EA and 830LA + EA groups showed significantly longer reaction times on day 15 (p < 0.01).
| Group | Day 0 (sec) | Day 8 (sec) | Day 15 (sec) |
|---|---|---|---|
| Nor | 6.42 ± 0.23 | 6.32 ± 0.29 | 6.40 ± 0.16 |
| Con | 6.62 ± 0.62 | 2.82 ± 0.31## | 3.53 ± 0.56## |
| MA | 6.43 ± 0.38 | 4.78 ± 0.35** | 5.32 ± 0.51 |
| EA | 6.70 ± 0.52 | 4.93 ± 0.49** | 5.68 ± 0.26** |
| 650LA | 6.57 ± 0.40 | 4.08 ± 0.53 | 4.83 ± 0.19 |
| 830LA | 6.47 ± 0.45 | 3.78 ± 0.67 | 5.38 ± 0.56 |
| 650LA + EA | 6.62 ± 0.21 | 4.70 ± 0.17** | 5.42 ± 0.60 |
| 830LA + EA | 6.37 ± 0.49 | 3.87 ± 0.62 | 6.23 ± 0.24** |
Table 4 shows the effect of each treatment on the von Frey force intensity for paclitaxel-induced allodynia. Compared to the Nor group, von Frey force intensity in the Con group was significantly lower on days 8 and 15 (p < 0.01). Compared to the Con group, significantly higher von Frey force intensity was observed in the MA, EA, and 650LA + EA groups on day 8 (p < 0.05), and in the EA and 830LA + EA groups on day 15 (p < 0.01).
| Group | Day 0 (g) | Day 8 (g) | Day 15 (g) |
|---|---|---|---|
| Nor | 35.75 ± 1.25 | 35.23 ± 1.59 | 35.69 ± 0.90 |
| Con | 36.88 ± 3.42 | 18.43 ± 1.17## | 20.82 ± 3.60## |
| MA | 35.85 ± 2.11 | 26.78 ± 1.95** | 28.97 ± 2.49 |
| EA | 37.32 ± 2.86 | 27.60 ± 2.73* | 31.72 ± 1.45* |
| 650LA | 36.58 ± 2.17 | 22.93 ± 2.93 | 27.05 ± 1.04 |
| 830LA | 36.05 ± 2.47 | 21.30 ± 3.70 | 34.02 ± 3.34* |
| 650LA + EA | 36.87 ± 1.14 | 26.33 ± 0.93** | 35.65 ± 2.68* |
| 830LA + EA | 35.47 ± 2.69 | 22.02 ± 3.42 | 34.75 ± 1.33** |
mRNA expression of CB1R and FAAH
CB1R mRNA expression in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 3.47 ± 0.23, 3.06 ± 0.18, 4.77 ± 0.03, 2.56 ± 0.07, 3.60 ± 0.18, 6.15 ± 0.19, and 2.99 ± 0.02, respectively (Figure 2A). There was a significant increase in CB1R mRNA in the Con group compared to the Nor group (p < 0.01), and a significant increase in CB1R mRNA in the 630LA + EA group compared to the Con group (p < 0.01).
The mRNA expression of FAAH in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 1.85 ± 0.48, 2.08 ± 0.04, 2.17 ± 0.02, 1.58 ± 0.04, 2.22 ± 0.07, 3.13 ± 0.24, and 2.68 ± 0.05, respectively (Figure 2B). Compared to the Nor group, the Con group showed a tendency to increased FAAH mRNA levels, while the 630LA + EA group showed a significant increase in FAAH mRNA compared to the Con group (p < 0.05).
Protein expression of c-Fos, CB1R, FAAH, NeuN, synapsin I, and MAP2
Figure 3A shows Western blotting results revealing the effect of each treatment on the expression of pain-related proteins, including c-Fos, CB1R, FAAH, NeuN, synapsin I, and MAP2.
The c-Fos protein expression in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 2.79 ± 0.33, 1.98 ± 0.30, 1.15 ± 0.09, 0.81 ± 0.02, 2.28 ± 0.25, 2.63 ± 0.55, and 0.52 ± 0.19, respectively (Figure 3B). Compared to the Nor group, the Con group showed significantly increased c-Fos protein expression (p < 0.01), while c-Fos protein levels in the EA, 650 LA, and 830 LA + EA group were significantly decreased compared to those in the Con group (p < 0.01).
The protein expression of CB1R in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 3.98 ± 0.02, 4.64 ± 0.58, 3.87 ± 0.09, 2.88 ± 0.03, 6.46 ± 0.15, 6.76 ± 0.28, and 8.23 ± 0.37, respectively (Figure 3C). Levels were significantly higher in the Con (3.98 ± 0.02) than in the Nor group (0.98 ± 0.01, p < 0.01). Compared to the Con group (p < 0.01), levels were significantly lower in the 650LA group and significantly higher in the 830LA, 650LA + EA, and 830LA + EA group.
The protein expression of FAAH in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 1.38 ± 0.51, 1.32 ± 0.09, 1.53 ± 0.19, 0.56 ± 0.01, 0.88 ± 0.01, 0.69 ± 0.02, and 0.24 ± 0.01, respectively (Figure 3D). Compared to the Nor group, the Con group showed a tendency to an increase in FAAH levels. The 830LA + EA group showed significantly decreased protein levels compared to the Con group (p < 0.05).
The protein expression of NeuN in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 4.59 ± 0.83, 2.64 ± 0.60, 1.89 ± 0.43, 0.92 ± 0.01, 2.77 ± 0.49, 4.73 ± 0.98, and 0.55 ± 0.09, respectively (Figure 3E). Compared to the Nor group, the Con group showed significantly increased protein expression of NeuN (p < 0.01), while the EA, 650LA, and 830LA + EA group showed significantly decreased protein levels compared to the Con group (p < 0.05, p < 0.01, and p < 0.01, respectively).
The protein expression of synapsin I in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 4.84 ± 0.31, 2.62 ± 0.15, 0.26 ± 0.06, 0.43 ± 0.06, 1.43 ± 0.14, 5.54 ± 1.48, and 0.15 ± 0.05, respectively (Figure 3F). Compared to the Nor group, the Con group showed significantly increased protein expression (p < 0.01). The MA, EA, 650LA, 830LA, and 830LA + EA group showed significantly decreased synapsin I levels compared to the Con group (p < 0.01).
The protein expression of MAP2 in the Nor, Con, MA, EA, 650LA, 830LA, 650LA + EA, and 830LA + EA group was 0.98 ± 0.01, 4.88 ± 0.47, 2.33 ± 0.31, 0.78 ± 0.15, 0.94 ± 0.07, 1.26 ± 0.07, 6.01 ± 0.79, and 0.11 ± 0.02, respectively (Figure 3G). Compared to the Nor group, the Con group showed significantly increased protein expression (p < 0.01), while levels were significantly lower in the MA, EA, 650LA, 830LA, and 830LA + EA group compared to the Con group (p < 0.01).
Metabolome analysis
PCA was performed to observe metabolome changes according to treatment type in the allodynia model, and quality control samples pooled from all samples were concentrated near the center of the PCA score plot, indicating that the GC–MS metabolome analysis was reproducible and reliable. Our analysis of pattern changes after different types of acupuncture procedures at the two acupuncture points yielded unclear results.
PCA and PLS-DA were performed to assess metabolome changes between the Nor and the Con group and between the Con group and each treatment group. The PCA results showed a large deviation in the repeat interval without differences between the Nor and the Con group. The PLS-DA analysis showed a tendency to separate between groups, but the permutation test analysis showed no significant difference (Q2 = 0.0145; Figure 4A).
The PCA results yielded no difference between the Con group and each treatment group. The PLS-DA results showed a tendency to separate between groups, but the permutation test analysis revealed no significant difference except for the 830LA + EA group. Although PCA yielded no difference between the Con and the 830LA + EA group, the PLS-DA results showed a pattern of separation between the two groups, and the permutation test analysis indicated a significant difference (Q2 = 0.5399; Figure 4B).
Discussion
This study shows significantly increased von Frey reaction times and force intensity in the MA, EA, and 650LA + EA group compared to the Con group on day 8. On day 15, the EA and the 830LA + EA group showed significantly increased von Frey reaction times and force intensity compared to the Con group. The von Frey filament quantifies the degree of pain, to ensure objectivity (31), and is used as an index to measure the degree of secondary hyperalgesia accompanying neuropathic or inflammatory pain (15). The von Frey index on day 8, when administration of paclitaxel was terminated, can be interpreted as indicating an analgesic effect, and the index on day 15, when the 9th treatment intervention was completed, seems to demonstrate an effect of damage repair and regeneration. The fact that the Con group had significantly decreased von Frey reaction times and force intensity on days 8 and 15 compared to the Nor group illustrates that paclitaxel blocks normal cell cycle progression and that apoptosis causes cell damage and allodynia. It seems that reaction times decreased because allodynia occurred and the animals felt pain, and that the force intensity decreased because movement was restricted by the pain. We assume that the MA, EA, and 650 LA + EA group exhibited a reliable analgesic effect, while the EA and the 830 LA + EA group demonstrated the effect of damage repair and regeneration. However, nociceptive and analgesic effects are affected by complex mechanisms including nociceptive, inflammatory, and neuropathic etiology and chemical and mechanical modality (32), it is important to comprehensively evaluate mechanical threshold values along with various factors related to pain in the body.
Among the three groups in which CB1R protein expression was significantly increased compared to the Con group, only the 650LA + EA group showed significantly increased mRNA expression of CB1R. CB1R is a cannabinoid receptor for a substance called anandamide, which is highly distributed in the central nervous system and involved in pain and neurodegeneration (7). It is mainly found in immune cells, such as B and T cells, and plays a role in immune responses and inflammation (33). Primarily expressed in presynaptic GABA and glutamate neurons, activation of CB1R by cannabinoids delivered from postsynaptic neurons can reduce the transmission of pain to the central nervous system by suppressing the release of GABA and glutamate in presynaptic neurons (34). In the current study, both mRNA and protein expression of CB1R were significantly increased when 650LA + EA treatment was applied, suggesting that the combination of 650-nm LA and EA can help reduce pain transmission. In addition, FAAH protein expression was significantly lower in the 830LA + EA group than in the control group. When endogenous cannabinoids bind to CB1R, they activate the receptor to induce analgesic action; otherwise, FAAH degrades the cannabinoids and the analgesic action does not last long (33). This therefore suggests a longer-lasting analgesic effect in the 830LA + EA group, which exhibited significantly lower FAAH protein levels than the other groups. The endocannabinoid system to which CB1R belongs is involved in the pain pathway and is composed of CB1R, CB2R, endocannabinoids such as transient receptor potential subfamily V member (TRPV) 1 and peroxisome proliferator-activated receptors (PPAR), and metabolizing enzymes (14). The endocannabinoid signaling system is regulated by synthesis and release of anandamide and 2-arachidonoylglycerol, uptake and degradation at supraspinal, spinal, and peripheral levels (8, 14, 35). Endocannabinoids are released activating CB1R, CB2R, and non-cannabinoid receptors including TRPV1 and PPAR (35). Released endocannabinoids are degraded by the hydrolyzing enzymes including FAAH and monoacylglycerol lipase, and by oxidative metabolism through cyclooxygenase, lipoxygenase and cytochrome P450 enzymes (8, 35). The endocannabinoid signaling mechanisms for modulating pain are related to enhancing endocannabinoids levels by inhibiting enzymes and blocking their reuptake, so further large-scale research is required to evaluate the complex therapeutic roles of the endocannabinoid system in various pain-related diseases.
This study also found significantly lower c-Fos protein levels in the EA, 650LA, and 830LA + EA group compared to the Con group. c-Fos is expressed in neurons in response to stimulation, and an increase in c-Fos is known to be associated with hypersensitivity to pain (36, 37). Compared to the Nor group, the Con group exhibited significantly increased c-Fos protein expression in the current study, which is consistent with a previous report that c-Fos protein is increased by noxious stimuli, such as thermal, mechanical, and chemical stimuli (9). These results indicate that treatment methods such as EA, 650LA, and 830LA + EA can have effects on pain relief in rats affected by allodynia, in line with the downregulation of c-Fos protein.
Only the 650LA + EA group showed a tendency to an increase in NeuN, synapsin I, and MAP2 levels compared to the Con group, although the difference was not significant. NeuN is a protein expressed in post-mitotic neurons that regulates neuronal growth (11, 12). Synapsin I is a type of neuronal phosphoprotein that binds to the cytoplasmic surface of synaptic vesicles and regulates synapse formation and neurotransmitter release through axonogenesis and synaptogenesis (10). MAP2 is a protein expressed by the MAP2 gene, and during cell division, microtubules extending from the centrosome bind to chromosomes to divide them (13). These three proteins are all involved in nerve regeneration, and the upregulation of the proteins in the 650LA + EA group therefore indicates the regeneration of paclitaxel-damaged neurons through therapeutic stimulation. 650LA + EA treatment can thus be expected to play an effective role in nerve regeneration.
The PLS-DA results of the metabolome analysis show a pattern of separation between the Con and the 830LA + EA group, and the permutation test analysis revealed a significant separation. These results indicate that treatment with 830LA + EA at the CV12 and ST36 acupoints brought about changes in the intestinal microflora and affected metabolomes. This suggests that 830-nm LA + EA could be more effective than other treatments in triggering changes in the microbial ecosystem in the large intestine through intestinal regulation.
This study has several limitations. First, the sample size for each group was relatively small. Second, among the six proteins used for our protein expression analysis, only mRNA for CB1R and FAAH could be confirmed. Additionally, correlation between proteins was not evaluated. Third, mRNA and protein expression was confirmed only in the spinal nerve tissues of rats, including the brain, spinal cord, and peripheral nerves. Lastly, pain assessment was performed using only the grimace scale. Despite these limitations, the present study shows the possibility of using LA combined with EA as an analgesic therapy for allodynia. We speculate that the combined treatment of EA and LA is helpful in pain relief and nerve regeneration, and induces changes in the intestinal microbiome.
In conclusion, the present study provides evidence that the combined treatment of EA and LA helps in pain relief and nerve regeneration and is effective in changing the intestinal microbiome. Among the different combination treatments, 650LA + EA induced upregulation of proteins related to pain relief and nerve regeneration, and 830LA + EA led to significant changes in metabolomes. These findings suggest the combined treatment of EA and LA as a useful method to relieve pain, such as in patients with allodynia. Further research is needed to assess the exact mechanism underlying the therapeutic effect of the combined treatment in pain-related diseases.
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Ethics statement
The animal study was reviewed and approved by the Committee of Animal Care and Experiment of Dongshin University, Republic of Korea (DSU2020-04-01).
Funding
This work is supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (No. HI21C1924), the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (No. 2022M3A9B6017813).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Untitled section
References
- 1.Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. (2000) 16:S12–20. doi: 10.1097/00002508-200006001-00004
- 2.Landerholm Å. Neuropathic Pain: Somatosensory Functions Related to Spontaneous Ongoing Pain, Mechanical Allodynia and Pain Relief. Solna: Karolinska Institutet (Sweden) (2010).
- 3.He Y, Kim PY. Allodynia StatPearls [internet]. Florida, United States: StatPearls Publishing; (2021).
- 4.Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. (2014) 13:924–35. doi: 10.1016/S1474-4422(14)70102-4, PMID:
- 5.Bae SB, Lee SC. Medical treatment of cancer pain: drug therapy according to guidelines will improve the quality of life of cancer patients. Korean J Med. (2018) 93:260–265.
- 6.Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cells. (2009) 139:267–84. doi: 10.1016/j.cell.2009.09.028, PMID:
- 7.Leo LM, Abood ME. CB1 cannabinoid receptor signaling and biased signaling. Molecules. (2021) 26:5413. doi: 10.3390/molecules26175413, PMID:
- 8.Miranda-Cortés A, Mota-Rojas D, Crosignani-Outeda N, Casas-Alvarado A, Martínez-Burnes J, Olmos-Hernández A, et al. The role of cannabinoids in pain modulation in companion animals. Front Vet Sci. (2023) 9:1050884. doi: 10.3389/fvets.2022.1050884
- 9.Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. (1987) 328:632–4. doi: 10.1038/328632a0, PMID:
- 10.Huttner W, Schiebler W, Greengard P, De Camilli P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol. (1983) 96:1374–88. doi: 10.1083/jcb.96.5.1374, PMID:
- 11.Lavezzi AM, Corna MF, Matturri L. Neuronal nuclear antigen (NeuN): a useful marker of neuronal immaturity in sudden unexplained perinatal death. J Neurol Sci. (2013) 329:45–50. doi: 10.1016/j.jns.2013.03.012, PMID:
- 12.Zhu S, Ying Y, Ye J, Chen M, Wu Q, Dou H, et al. AAV2-mediated and hypoxia response element-directed expression of bFGF in neural stem cells showed therapeutic effects on spinal cord injury in rats. Cell Death Dis. (2021) 12:274. doi: 10.1038/s41419-021-03546-6
- 13.Vale RD. The molecular motor toolbox for intracellular transport. Cells. (2003) 112:467–80. doi: 10.1016/S0092-8674(03)00111-9, PMID:
- 14.Starowicz K, Finn DP. Cannabinoids and pain: sites and mechanisms of action. Adv Pharmacol. (2017) 80:437–75. doi: 10.1016/bs.apha.2017.05.003, PMID:
- 15.Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene. (2001) 20:6123–31. doi: 10.1038/sj.onc.1204712, PMID:
- 16.Chang JH, Kim KY, Ahn SC, Kwon HY. Relation of poly (ADP-ribose) polymerase cleavage and apoptosis induced by paclitaxel in HeLa S 3 uterine cancer cells. J Life Sci. (2007) 17:1027–33. doi: 10.5352/JLS.2007.17.8.1027
- 17.Staff NP. Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S. Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. (2020) 324:113121. doi: 10.1016/j.expneurol.2019.113121, PMID:
- 18.Wu J, Hocevar M, Bie B, Foss JF, Naguib M. Cannabinoid type 2 receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats. J Pain. (2019) 20:501–14. doi: 10.1016/j.jpain.2018.10.007, PMID:
- 19.Park SI, Sunwoo Y-Y, Jung YJ, Chang WC, Park M-S, Chung Y-A, et al. Therapeutic effects of acupuncture through enhancement of functional angiogenesis and granulogenesis in rat wound healing. Evid Based Complement Alternat Med. (2012) 2012:1–10. doi: 10.1155/2012/464586, PMID:
- 20.Maeda Y, Kim H, Kettner N, Kim J, Cina S, Malatesta C, et al. Rewiring the primary somatosensory cortex in carpal tunnel syndrome with acupuncture. Brain. (2017) 140:914–27. doi: 10.1093/brain/awx015, PMID:
- 21.Yi YJ, Kim DH, Chang S, Ryu Y, Kim SC, Kim HY. Electroacupuncture at neurogenic spots in referred pain areas attenuates hepatic damages in bile duct-ligated rats. Int J Mol Sci. (2021) 22:1974. doi: 10.3390/ijms22041974, PMID:
- 22.Zhang L, Tang Y, Hui R, Zheng H, Deng Y, Shi Y, et al. The effects of active acupuncture and placebo acupuncture on insomnia patients: a randomized controlled trial. Psychol Health Med. (2020) 25:1201–15. doi: 10.1080/13548506.2020.1738015
- 23.Kim M, Lee Y, Choi D, Youn D, Na C. Effects of laser and electro acupuncture treatment with GB30· GB34 on change in arthritis rat. Korean J Acupunct. (2019) 36:189–99. doi: 10.14406/acu.2019.023
- 24.Wu SY, Lin CH, Chang NJ, Hu WL, Hung YC, Tsao Y, et al. Combined effect of laser acupuncture and electroacupuncture in knee osteoarthritis patients: a protocol for a randomized controlled trial. Medicine. (2020) 99:e19541. doi: 10.1097/MD.0000000000019541
- 25.Koh H-K. Transpositional acupoints of the mouse. J Acupunct Res. (2001) 18:225–31.
- 26.Js K, Ys K, Ss N. The mechanism of immunomodulatory effect by electro-acupuncture in 2, 4-Dinitrophenylated keyhole limpet protein immunized mice. J Acupunct Res. (2005) 22:23–35.
- 27.Cai R, Guan Y, Wu H, Xu C, Li C, Hu L, et al. Effects on the regional homogeneity of resting-state brain function in the healthy subjects of gastric distention treated with acupuncture at the front-mu and back-shu points of the stomach, Weishu (BL 21) and Zhongwan (CV 12). Zhongguo Zhen jiu= Chin Acupunct Moxibustion. (2018) 38:379–86. doi: 10.13703/j.0255-2930.2018.04.010, PMID:
- 28.Jeon WK. Complement and integrative approach in gut health and immunologic disease. Hanyang Med Rev. (2010) 30:109–14. doi: 10.7599/hmr.2010.30.2.109
- 29.Tian L, Huang Y-X, Tian M, Gao W, Chang Q. Downregulation of electroacupuncture at ST36 on TNF-α in rats with ulcerative colitis. World J Gastroenterol: WJG. (2003) 9:1028–33. doi: 10.3748/wjg.v9.i5.1028, PMID:
- 30.Zhu X, Liu Z, Qin Y, Niu W, Wang Q, Li L, et al. Analgesic effects of electroacupuncture at ST25 and CV12 in a rat model of postinflammatory irritable bowel syndrome visceral pain. Acupunct Med. (2018) 36:240–6. doi: 10.1136/acupmed-2016-011320, PMID:
- 31.Shir Y, Ze S. Effects of sympathectomy in a model of causalgiform pain produced by partial sciatic nerve injury in rats. Pain. (1991) 45:309–20. doi: 10.1016/0304-3959(91)90056-4, PMID:
- 32.Elhabazi K, Ayachi S, Ilien B, Simonin F. Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities. J Vis Exp. (2014) 89:e51264. doi: 10.3791/51264
- 33.Goutopoulos A, Fan P, Khanolkar AD, Xie X-Q, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem. (2001) 9:1673–84. doi: 10.1016/S0968-0896(01)00088-8, PMID:
- 34.Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol. (2008) 184:435–77. doi: 10.1007/978-3-540-74805-2_14
- 35.Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. (2009) 8:403–21. doi: 10.2174/187152709789824660
- 36.Harris JA. Using c-fos as a neural marker of pain. Brain Res Bull. (1998) 45:1–8. doi: 10.1016/S0361-9230(97)00277-3
- 37.Touj S, Tokunaga R, Al Aïn S, Bronchti G, Piché M. Pain hypersensitivity is associated with increased amygdala volume and c-Fos immunoreactivity in anophthalmic mice. Neuroscience. (2019) 418:37–49. doi: 10.1016/j.neuroscience.2019.08.035, PMID:
Associated Data
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.